我院516例急性心肌梗死患者二级预防药物应用调查与分析
x

请在关注微信后,向客服人员索取文件

篇名: 我院516例急性心肌梗死患者二级预防药物应用调查与分析
TITLE:
摘要: 目的:为急性心肌梗死患者合理使用二级预防药物提供参考。方法:收集我院心血管内科2013年1月-2015年6月出院的急性心肌梗死患者的病例资料,对抗栓药[阿司匹林、二磷酸腺苷(ADP)受体拮抗药]、调脂药(他汀类药物)、神经内分泌抑制剂[血管紧张素转换酶抑制剂(ACEI)或血管紧张素Ⅱ受体拮抗药(ARB)、β受体阻滞药]的使用情况进行分析。结果:共纳入516例患者,排除禁忌证后,药物使用率分别为阿司匹林100%、ADP受体拮抗药100%、他汀类调脂药100%、ACEI/ARB 66.4%、β受体阻滞药85.3%。剂量达标率分别为阿司匹林100%、ADP受体拮抗药98.8%、他汀类调脂药99.4%、ACEI/ARB 82.0%、β受体阻滞药64.8%。共有33例患者出现药品不良反应。结论:我院急性心肌梗死患者抗栓药、调脂药使用较合理,神经内分泌抑制剂的使用仍与指南存在一定差距。
ABSTRACT: OBJECTIVE: To provide reference for rational use of secondary prevention drugs in patients with acute myocardial infarction. METHODS: The use of the drugs, including antithrombotic drugs (aspirin and ADP receptor antagonist), lipid-lowering drugs (statins), neuroendocrine inhibitors (ACEI or ARB and β-blocker) were analyzed with the data taken from the discharged cases with acute myocardial infarction from Jan. 2013 to Jun. 2015. RESULTS: 516 cases were enrolled. The utilization rates of aspirin, ADP receptor antagonist, statins, ACEI/ARB and β-blocker were 100%, 100%, 100%, 66.4% and 85.3%. The rates of reaching standard dose were 100%, 98.8%, 99.4%, 82.0% and 64.8%. A total of 33 cases suffered from ADR. CONCLUSIONS: The use of antithrombotic drugs and lipid-lowering drugs are rational relatively in our hospital, but there is still a certain gap between clinical practice and guideline in the use of neuroendocrine inhibitors.
期刊: 2016年第27卷第14期
作者: 李静,蒋林轩,赵敏
AUTHORS: LI Jing,JIANG Linxuan,ZHAO Min
关键字: 急性心肌梗死;二级预防;抗栓药;调脂药;神经内分泌抑制剂
KEYWORDS: Acute myocardial infarction; Secondary prevention; Antithrombotic drugs; Lipid-lowering drugs; Neuroendocrine inhibitors
阅读数: 117 次
本月下载数: 2 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!